Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 223 articles:
HTML format

Single Articles

    January 2021
  1. KERN I, Schoffer O, Kiess W, Henker J, et al
    Incidence trends of pediatric onset inflammatory bowel disease in the years 2000-2009 in Saxony, Germany-first results of the Saxon Pediatric IBD Registry.
    PLoS One. 2021;16:e0243774.
    PubMed     Abstract available

  2. KONSTANTINIDIS AO, Adamama-Moraitou KK, Pardali D, Dovas CI, et al
    Colonic mucosal and cytobrush sample cytokine mRNA expression in canine inflammatory bowel disease and their correlation with disease activity, endoscopic and histopathologic score.
    PLoS One. 2021;16:e0245713.
    PubMed     Abstract available

  3. NAFTALI T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, et al
    Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.
    PLoS One. 2021;16:e0246871.
    PubMed     Abstract available

  4. REVILLA L, Mayorgas A, Corraliza AM, Masamunt MC, et al
    Multi-omic modelling of inflammatory bowel disease with regularized canonical correlation analysis.
    PLoS One. 2021;16:e0246367.
    PubMed     Abstract available

  5. DING ZH, Xu XP, Wang TR, Liang X, et al
    The prevalence of Helicobacter pylori infection in inflammatory bowel disease in China: A case-control study.
    PLoS One. 2021;16:e0248427.
    PubMed     Abstract available

  6. RANA T, Korolkova OY, Rachakonda G, Williams AD, et al
    Linking bacterial enterotoxins and alpha defensin 5 expansion in the Crohn's colitis: A new insight into the etiopathogenetic and differentiation triggers driving colonic inflammatory bowel disease.
    PLoS One. 2021;16:e0246393.
    PubMed     Abstract available

  7. ARKTEG CB, Wergeland Sorbye S, Buhl Riis L, Dalen SM, et al
    Real-life evaluation of histologic scores for Ulcerative Colitis in remission.
    PLoS One. 2021;16:e0248224.
    PubMed     Abstract available

  8. TAMAN H, Fenton CG, Anderssen E, Florholmen J, et al
    DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis.
    PLoS One. 2021;16:e0248905.
    PubMed     Abstract available

  9. FURUSE M, Hosomi S, Nishida Y, Itani S, et al
    The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.
    PLoS One. 2021;16:e0250597.
    PubMed     Abstract available

  10. XU F, Park S, Liu Y, Greenlund KJ, et al
    Dietary intake patterns among adults with inflammatory bowel disease in the United States, 2015.
    PLoS One. 2021;16:e0250441.
    PubMed     Abstract available

  11. ISHIDA N, Higuchi T, Miyazu T, Tamura S, et al
    Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease.
    PLoS One. 2021;16:e0250658.
    PubMed     Abstract available

  12. BUSINGYE D, Pollack A, Chidwick K
    Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study.
    PLoS One. 2021;16:e0252458.
    PubMed     Abstract available

  13. TREFZER R, Elpeleg O, Gabrusskaya T, Stepensky P, et al
    Characterization of a L136P mutation in Formin-like 2 (FMNL2) from a patient with chronic inflammatory bowel disease.
    PLoS One. 2021;16:e0252428.
    PubMed     Abstract available

  14. YEN HH, Su PY, Huang SP, Wu L, et al
    Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
    PLoS One. 2021;16:e0252286.
    PubMed     Abstract available

  15. SMITH SCL, Banbury C, Zardo D, Cannatelli R, et al
    Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease.
    PLoS One. 2021;16:e0252210.
    PubMed     Abstract available

  16. CAPITANO ML, Jaiswal A, Broxmeyer HE, Pride Y, et al
    A humanized monoclonal antibody against the endothelial chemokine CCL21 for the diagnosis and treatment of inflammatory bowel disease.
    PLoS One. 2021;16:e0252805.
    PubMed     Abstract available

  17. KATO M, Sugimoto K, Ikeya K, Takano R, et al
    Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
    PLoS One. 2021;16:e0254548.
    PubMed     Abstract available

    January 2020
  18. ARMUZZI A, DiBonaventura MD, Tarallo M, Lucas J, et al
    Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe.
    PLoS One. 2020;15:e0227914.
    PubMed     Abstract available

  19. CIAPPONI A, Virgilio SA, Berrueta M, Soto NC, et al
    Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study.
    PLoS One. 2020;15:e0228256.
    PubMed     Abstract available

  20. JODELEIT H, Milchram L, Soldo R, Beikircher G, et al
    Autoantibodies as diagnostic markers and potential drivers of inflammation in ulcerative colitis.
    PLoS One. 2020;15:e0228615.
    PubMed     Abstract available

  21. DANG X, Xu M, Liu D, Zhou D, et al
    Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0228846.
    PubMed     Abstract available

  22. YU TB, Dodd S, Yu LG, Subramanian S, et al
    Serum galectins as potential biomarkers of inflammatory bowel diseases.
    PLoS One. 2020;15:e0227306.
    PubMed     Abstract available

  23. LIM WW, Ng B, Widjaja A, Xie C, et al
    Transgenic interleukin 11 expression causes cross-tissue fibro-inflammation and an inflammatory bowel phenotype in mice.
    PLoS One. 2020;15:e0227505.
    PubMed     Abstract available

  24. KUBESCH A, Boulahrout P, Filmann N, Blumenstein I, et al
    Real-world data about emotional stress, disability and need for social care in a German IBD patient cohort.
    PLoS One. 2020;15:e0227309.
    PubMed     Abstract available

  25. HAN MK, Anderson R, Viennois E, Merlin D, et al
    Examination of food consumption in United States adults and the prevalence of inflammatory bowel disease using National Health Interview Survey 2015.
    PLoS One. 2020;15:e0232157.
    PubMed     Abstract available

  26. YAMAMOTO-FURUSHO JK, Mendieta-Escalante EA
    Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis.
    PLoS One. 2020;15:e0231988.
    PubMed     Abstract available

  27. HAZLEWOOD GS, Pokharel G, Deardon R, Marshall DA, et al
    Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment.
    PLoS One. 2020;15:e0227635.
    PubMed     Abstract available

  28. BROKERHOF IM, Ybema JF, Bal PM
    Illness narratives and chronic patients' sustainable employability: The impact of positive work stories.
    PLoS One. 2020;15:e0228581.
    PubMed     Abstract available

  29. KUNOVSZKI P, Milassin A, Gimesi-Orszagh J, Takacs P, et al
    Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary - a population-based study.
    PLoS One. 2020;15:e0233238.
    PubMed     Abstract available

  30. MAVROPOULOU E, Mechie NC, Knoop R, Petzold G, et al
    Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study.
    PLoS One. 2020;15:e0233811.
    PubMed     Abstract available

  31. BURISCH J, Eigner W, Schreiber S, Aletaha D, et al
    Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0233781.
    PubMed     Abstract available

  32. ARAKI M, Shinzaki S, Yamada T, Arimitsu S, et al
    Psychologic stress and disease activity in patients with inflammatory bowel disease: A multicenter cross-sectional study.
    PLoS One. 2020;15:e0233365.
    PubMed     Abstract available

  33. PARK J, Yoon H, Shin CM, Park YS, et al
    Higher levels of disease-related knowledge reduce medical acceleration in patients with inflammatory bowel disease.
    PLoS One. 2020;15:e0233654.
    PubMed     Abstract available

  34. SCOVILLE EA, Tindle HA, Wells QS, Peyton SC, et al
    Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study.
    PLoS One. 2020;15:e0230656.
    PubMed     Abstract available

  35. WANG J, Ortiz C, Fontenot L, Xie Y, et al
    High circulating elafin levels are associated with Crohn's disease-associated intestinal strictures.
    PLoS One. 2020;15:e0231796.
    PubMed     Abstract available

  36. ZHOU M, Xu R, Kaelber DC, Gurney ME, et al
    Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis.
    PLoS One. 2020;15:e0229819.
    PubMed     Abstract available

  37. KANG EA, Chun J, Im JP, Lee HJ, et al
    Anemia is associated with the risk of Crohn's disease, not ulcerative colitis: A nationwide population-based cohort study.
    PLoS One. 2020;15:e0238244.
    PubMed     Abstract available

  38. WIDBOM L, Schneede J, Midttun O, Ueland PM, et al
    Elevated plasma cotinine is associated with an increased risk of developing IBD, especially among users of combusted tobacco.
    PLoS One. 2020;15:e0235536.
    PubMed     Abstract available

  39. HALE LP
    Deficiency of activation-induced cytidine deaminase in a murine model of ulcerative colitis.
    PLoS One. 2020;15:e0239295.
    PubMed     Abstract available

  40. TABORELLI M, Sozzi M, Del Zotto S, Toffolutti F, et al
    Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy.
    PLoS One. 2020;15:e0235142.
    PubMed     Abstract available

  41. PARK A, Kim S, Jung IH, Byun JH, et al
    An immune therapy model for effective treatment on inflammatory bowel disease.
    PLoS One. 2020;15:e0238918.
    PubMed     Abstract available

  42. CALDEIRA LF, Borba HH, Tonin FS, Wiens A, et al
    Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0238910.
    PubMed     Abstract available

  43. SCHNITZLER F, Friedrich M, Angelberger M, Diegelmann J, et al
    Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery.
    PLoS One. 2020;15:e0236421.
    PubMed     Abstract available

  44. CAI B, Zhou MH, Huang HL, Zhou AC, et al
    Protective effects of citrulline supplementation in ulcerative colitis rats.
    PLoS One. 2020;15:e0240883.
    PubMed     Abstract available

  45. ALLAIS L, Verschuere S, Maes T, De Smet R, et al
    Translational research into the effects of cigarette smoke on inflammatory mediators and epithelial TRPV1 in Crohn's disease.
    PLoS One. 2020;15:e0236657.
    PubMed     Abstract available

  46. NISHIDA Y, Hosomi S, Yamagami H, Fujimoto K, et al
    Novel prognostic biomarkers of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: Neutrophil-to-lymphocyte ratio.
    PLoS One. 2020;15:e0241322.
    PubMed     Abstract available

  47. UCHIYAMA K, Takami S, Suzuki H, Umeki K, et al
    Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis: An investigator-initiated multicenter double-blind clinical trial.
    PLoS One. 2020;15:e0241337.
    PubMed     Abstract available

  48. HOFFMANN P, Behnisch R, Gsenger J, Schnitzler P, et al
    Hepatitis E seroprevalence in a German cohort of patients with inflammatory bowel diseases.
    PLoS One. 2020;15:e0239825.
    PubMed     Abstract available

  49. LIMSRIVILAI J, Lee CK, Prueksapanich P, Harinwan K, et al
    Validation of models using basic parameters to differentiate intestinal tuberculosis from Crohn's disease: A multicenter study from Asia.
    PLoS One. 2020;15:e0242879.
    PubMed     Abstract available

  50. DOMENIS R, Marino M, Cifu A, Scardino G, et al
    Circulating exosomes express alpha4beta7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    PLoS One. 2020;15:e0242342.
    PubMed     Abstract available

  51. LI LN, Liu Y, Zhang HC, Wu T, et al
    Helicobacter pylori infection reduces TAMs infiltration in a mouse model of AOM/DSS induced colitis-associated cancer.
    PLoS One. 2020;15:e0241840.
    PubMed     Abstract available

    January 2019
  52. BURNETT-HARTMAN AN, Hua X, Rue TC, Golchin N, et al
    Risk interval analysis of emergency room visits following colonoscopy in patients with inflammatory bowel disease.
    PLoS One. 2019;14:e0210262.
    PubMed     Abstract available

  53. HUH G, Yoon H, Choi YJ, Shin CM, et al
    Trends in emergency department visits and hospitalization rates for inflammatory bowel disease in the era of biologics.
    PLoS One. 2019;14:e0210703.
    PubMed     Abstract available

  54. ROTH N, Biedermann L, Fournier N, Butter M, et al
    Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
    PLoS One. 2019;14:e0210436.
    PubMed     Abstract available

  55. CHIBA H, Kakuta Y, Kinouchi Y, Kawai Y, et al
    Correction: Allele-specific DNA methylation of disease susceptibility genes in Japanese patients with inflammatory bowel disease.
    PLoS One. 2019;14:e0212148.
    PubMed     Abstract available

  56. CHOI EJ, Lee HJ, Kim WJ, Han KI, et al
    Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model.
    PLoS One. 2019;14:e0210854.
    PubMed     Abstract available

  57. GONZALEZ-LOPEZ E, Kawasawa-Imamura Y, Zhang L, Huang X, et al
    A single nucleotide polymorphism in dopamine beta hydroxylase (rs6271(C>T)) is over-represented in inflammatory bowel disease patients and reduces circulating enzyme.
    PLoS One. 2019;14:e0210175.
    PubMed     Abstract available

  58. MOTOYA S, Watanabe K, Ogata H, Kanai T, et al
    Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
    PLoS One. 2019;14:e0212989.
    PubMed     Abstract available

  59. NISHIDA Y, Hosomi S, Yamagami H, Sugita N, et al
    Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction.
    PLoS One. 2019;14:e0213505.
    PubMed     Abstract available

  60. LEE J, Jee SR, Kim HW, Baek DH, et al
    Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis.
    PLoS One. 2019;14:e0214129.
    PubMed     Abstract available

  61. MOTOYA S, Watanabe K, Ogata H, Kanai T, et al
    Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
    PLoS One. 2019;14:e0215491.
    PubMed     Abstract available

  62. REISDORF WC, Xie Q, Zeng X, Xie W, et al
    Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.
    PLoS One. 2019;14:e0215033.
    PubMed     Abstract available

  63. KALENYAK K, Heilmann RM, van de Lest CHA, Brouwers JF, et al
    Comparison of the systemic phospholipid profile in dogs diagnosed with idiopathic inflammatory bowel disease or food-responsive diarrhea before and after treatment.
    PLoS One. 2019;14:e0215435.
    PubMed     Abstract available

  64. HILLER A, Biedermann L, Fournier N, Butter M, et al
    The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort.
    PLoS One. 2019;14:e0211554.
    PubMed     Abstract available

  65. LEE JG, Han DS, Jo SV, Lee AR, et al
    Characteristics and pathogenic role of adherent-invasive Escherichia coli in inflammatory bowel disease: Potential impact on clinical outcomes.
    PLoS One. 2019;14:e0216165.
    PubMed     Abstract available

  66. HUH G, Yoon H, Choi YJ, Shin CM, et al
    Correction: Trends in emergency department visits and hospitalization rates for inflammatory bowel disease in the era of biologics.
    PLoS One. 2019;14:e0216768.
    PubMed     Abstract available

  67. JANSSEN CE, Globig AM, Busse Grawitz A, Bettinger D, et al
    Seasonal variability of vitamin D status in patients with inflammatory bowel disease - A retrospective cohort study.
    PLoS One. 2019;14:e0217238.
    PubMed     Abstract available

  68. TOKSVANG LN, Schmidt MS, Arup S, Larsen RH, et al
    Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review.
    PLoS One. 2019;14:e0212157.
    PubMed     Abstract available

  69. FRENKEL S, Bernstein CN, Sargent M, Kuang Q, et al
    Genome-wide analysis identifies rare copy number variations associated with inflammatory bowel disease.
    PLoS One. 2019;14:e0217846.
    PubMed     Abstract available

  70. SOONTARARAK S, Chow L, Johnson V, Coy J, et al
    Humoral immune responses against gut bacteria in dogs with inflammatory bowel disease.
    PLoS One. 2019;14:e0220522.
    PubMed     Abstract available

  71. RUIZ HH, Becker S, Bai Y, Cortes-Burgos LA, et al
    Pharmacological inhibition of NPY receptors illustrates dissociable features of experimental colitis in the mouse DSS model: Implications for preclinical evaluation of efficacy in an inflammatory bowel disease model.
    PLoS One. 2019;14:e0220156.
    PubMed     Abstract available

  72. WITTNER M, Schlicker V, Libera J, Bockmann JH, et al
    Comparison of the integrin alpha4beta7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.
    PLoS One. 2019;14:e0220008.
    PubMed     Abstract available

  73. NAGANUMA M, Hirai F, Kobayashi K, Watanabe K, et al
    Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam.
    PLoS One. 2019;14:e0220413.
    PubMed     Abstract available

  74. THOMAS T, Chandan JS, Li VSW, Lai CY, et al
    Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts.
    PLoS One. 2019;14:e0221961.
    PubMed     Abstract available

  75. DEURING JJ, Li M, Cao W, Chen S, et al
    Pregnane X receptor activation constrains mucosal NF-kappaB activity in active inflammatory bowel disease.
    PLoS One. 2019;14:e0221924.
    PubMed     Abstract available

  76. PALMER NP, Silvester JA, Lee JJ, Beam AL, et al
    Concordance between gene expression in peripheral whole blood and colonic tissue in children with inflammatory bowel disease.
    PLoS One. 2019;14:e0222952.
    PubMed     Abstract available

  77. BATHE AL, Mavropoulou E, Mechie NC, Petzold G, et al
    Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis.
    PLoS One. 2019;14:e0223893.
    PubMed     Abstract available

  78. COLLIJ V, Imhann F, Vich Vila A, Fu J, et al
    SLC39A8 missense variant is associated with Crohn's disease but does not have a major impact on gut microbiome composition in healthy subjects.
    PLoS One. 2019;14:e0211328.
    PubMed     Abstract available

  79. VON MARTELS JZH, Bourgonje AR, Harmsen HJM, Faber KN, et al
    Assessing intestinal permeability in Crohn's disease patients using orally administered 52Cr-EDTA.
    PLoS One. 2019;14:e0211973.
    PubMed     Abstract available

  80. MATTHEWS SM, Eshelman MA, Berg AS, Koltun WA, et al
    The Crohn's disease associated SNP rs6651252 impacts MYC gene expression in human colonic epithelial cells.
    PLoS One. 2019;14:e0212850.
    PubMed     Abstract available

  81. SAGAMI S, Kobayashi T, Kikkawa N, Umeda S, et al
    Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease.
    PLoS One. 2019;14:e0212404.
    PubMed     Abstract available

  82. GOLL R, Heitmann R, Moe OK, Carlsen K, et al
    Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis.
    PLoS One. 2019;14:e0224895.
    PubMed     Abstract available

  83. ATHERLY T, Rossi G, White R, Seo YJ, et al
    Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease.
    PLoS One. 2019;14:e0226780.
    PubMed     Abstract available

  84. HAISMA SM, Galaurchi A, Almahwzi S, Adekanmi Balogun JA, et al
    Head-to-head comparison of three stool calprotectin tests for home use.
    PLoS One. 2019;14:e0214751.
    PubMed     Abstract available

  85. COLONETTI K, Bento Dos Santos B, Nalin T, Moura de Souza CF, et al
    Hepatic glycogen storage diseases are associated to microbial dysbiosis.
    PLoS One. 2019;14:e0214582.
    PubMed     Abstract available

  86. LI E, Zhang Y, Tian X, Wang X, et al
    Influence of Crohn's disease related polymorphisms in innate immune function on ileal microbiome.
    PLoS One. 2019;14:e0213108.
    PubMed     Abstract available

  87. ROBINSON SC, Chaudhary R, Jimenez-Saiz R, Rayner LGA, et al
    Kaiso-induced intestinal inflammation is preceded by diminished E-cadherin expression and intestinal integrity.
    PLoS One. 2019;14:e0217220.
    PubMed     Abstract available

  88. KONDO K, Ohfuji S, Watanabe K, Yamagami H, et al
    The association between environmental factors and the development of Crohn's disease with focusing on passive smoking: A multicenter case-control study in Japan.
    PLoS One. 2019;14:e0216429.
    PubMed     Abstract available

  89. SAMARANI S, Mack DR, Bernstein CN, Iannello A, et al
    Activating Killer-cell Immunoglobulin-like Receptor genes confer risk for Crohn's disease in children and adults of the Western European descent: Findings based on case-control studies.
    PLoS One. 2019;14:e0217767.
    PubMed     Abstract available

  90. BON L, Scharl S, Vavricka S, Rogler G, et al
    Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study.
    PLoS One. 2019;14:e0215738.
    PubMed     Abstract available

  91. TALPIN A, Kattah MG, Advincula R, Fadrosh D, et al
    A20 in dendritic cells restrains intestinal anti-bacterial peptide expression and preserves commensal homeostasis.
    PLoS One. 2019;14:e0218999.
    PubMed     Abstract available

  92. MARKOTA A, Metzger R, Heiseke AF, Jandl L, et al
    Comparison of iron-reduced and iron-supplemented semisynthetic diets in T cell transfer colitis.
    PLoS One. 2019;14:e0218332.
    PubMed     Abstract available

  93. HOLOTA Y, Dovbynchuk T, Kaji I, Vareniuk I, et al
    The long-term consequences of antibiotic therapy: Role of colonic short-chain fatty acids (SCFA) system and intestinal barrier integrity.
    PLoS One. 2019;14:e0220642.
    PubMed     Abstract available

  94. ADLER J, Jary HK, Eder SJ, Dong S, et al
    Identifying perianal fistula complications in pediatric patients with Crohn's disease using administrative claims.
    PLoS One. 2019;14:e0219893.
    PubMed     Abstract available

  95. BOTTOMS L, Leighton D, Carpenter R, Anderson S, et al
    Affective and enjoyment responses to 12 weeks of high intensity interval training and moderate continuous training in adults with Crohn's disease.
    PLoS One. 2019;14:e0222060.
    PubMed     Abstract available

  96. WOLOSZYNEK S, Mell JC, Zhao Z, Simpson G, et al
    Exploring thematic structure and predicted functionality of 16S rRNA amplicon data.
    PLoS One. 2019;14:e0219235.
    PubMed     Abstract available

  97. ABBAS M, Matta J, Le T, Bensmail H, et al
    Biomarker discovery in inflammatory bowel diseases using network-based feature selection.
    PLoS One. 2019;14:e0225382.
    PubMed     Abstract available

  98. KUBOTA M, Kakimoto K, Nakagawa T, Koubayashi E, et al
    Autophagy deficiency exacerbates colitis through excessive oxidative stress and MAPK signaling pathway activation.
    PLoS One. 2019;14:e0225066.
    PubMed     Abstract available

  99. COOPE A, Pascoal LB, Botezelli JD, da Silva FAR, et al
    ER stress activation in the intestinal mucosa but not in mesenteric adipose tissue is associated with inflammation in Crohn's disease patients.
    PLoS One. 2019;14:e0223105.
    PubMed     Abstract available

    January 2018
  100. MENDALL M, Harpsoe MC, Kumar D, Andersson M, et al
    Relation of body mass index to risk of developing inflammatory bowel disease amongst women in the Danish National Birth Cohort.
    PLoS One. 2018;13:e0190600.
    PubMed     Abstract available

  101. MINTZ M, Khair S, Grewal S, LaComb JF, et al
    Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.
    PLoS One. 2018;13:e0190997.
    PubMed     Abstract available

  102. DE BRUYN JR, Becker MA, Steenkamer J, Wildenberg ME, et al
    Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease.
    PLoS One. 2018;13:e0190999.
    PubMed     Abstract available

  103. GARCIA-SANJUAN S, Lillo-Crespo M, Richart-Martinez M, Sanjuan-Quiles A, et al
    Healthcare professionals' views of the experiences of individuals living with Crohn's Disease in Spain. A qualitative study.
    PLoS One. 2018;13:e0190980.
    PubMed     Abstract available

  104. BALBAS-MARTINEZ V, Ruiz-Cerda L, Irurzun-Arana I, Gonzalez-Garcia I, et al
    A systems pharmacology model for inflammatory bowel disease.
    PLoS One. 2018;13:e0192949.
    PubMed     Abstract available

  105. MIJAC D, Vukovic-Petrovic I, Mijac V, Perovic V, et al
    MDR1 gene polymorphisms are associated with ulcerative colitis in a cohort of Serbian patients with inflammatory bowel disease.
    PLoS One. 2018;13:e0194536.
    PubMed     Abstract available

  106. BUHNER S, Hahne H, Hartwig K, Li Q, et al
    Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients.
    PLoS One. 2018;13:e0193943.
    PubMed     Abstract available

  107. CHIBA H, Kakuta Y, Kinouchi Y, Kawai Y, et al
    Allele-specific DNA methylation of disease susceptibility genes in Japanese patients with inflammatory bowel disease.
    PLoS One. 2018;13:e0194036.
    PubMed     Abstract available

  108. KAMM F, Strauch U, Degenhardt F, Lopez R, et al
    Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease.
    PLoS One. 2018;13:e0194222.
    PubMed     Abstract available

  109. KOVACS G, Sipeki N, Suga B, Tornai T, et al
    Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.
    PLoS One. 2018;13:e0194166.
    PubMed     Abstract available

  110. MORAN CJ, Huang H, Rivas M, Kaplan JL, et al
    Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis.
    PLoS One. 2018;13:e0192806.
    PubMed     Abstract available

  111. SAITO H, Hirayama A, Umemura T, Joshita S, et al
    Association between KIR-HLA combination and ulcerative colitis and Crohn's disease in a Japanese population.
    PLoS One. 2018;13:e0195778.
    PubMed     Abstract available

  112. WALJEE AK, Wiitala WL, Govani S, Stidham R, et al
    Correction: Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort.
    PLoS One. 2018;13:e0197341.
    PubMed     Abstract available

  113. KUTSUNA R, Tomida J, Morita Y, Kawamura Y, et al
    Paraclostridium bifermentans exacerbates pathosis in a mouse model of ulcerative colitis.
    PLoS One. 2018;13:e0197668.
    PubMed     Abstract available

  114. BOURGONJE AR, von Martels JZH, de Vos P, Faber KN, et al
    Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines.
    PLoS One. 2018;13:e0193202.
    PubMed     Abstract available

  115. ANAND U, Yiangou Y, Akbar A, Quick T, et al
    Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons.
    PLoS One. 2018;13:e0198024.
    PubMed     Abstract available

  116. TIWARI V, Kedia S, Garg SK, Rampal R, et al
    CD4+ CD25+ FOXP3+ T cell frequency in the peripheral blood is a biomarker that distinguishes intestinal tuberculosis from Crohn's disease.
    PLoS One. 2018;13:e0193433.
    PubMed     Abstract available

  117. GRAY MA, Chao CY, Staudacher HM, Kolosky NA, et al
    Anti-TNFalpha therapy in IBD alters brain activity reflecting visceral sensory function and cognitive-affective biases.
    PLoS One. 2018;13:e0193542.
    PubMed     Abstract available

  118. STEWART DC, Berrie D, Li J, Liu X, et al
    Quantitative assessment of intestinal stiffness and associations with fibrosis in human inflammatory bowel disease.
    PLoS One. 2018;13:e0200377.
    PubMed     Abstract available

  119. YANG BR, Choi NK, Kim MS, Chun J, et al
    Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients.
    PLoS One. 2018;13:e0200363.
    PubMed     Abstract available

  120. GOVANI SM, Higgins PDR, Rubenstein JH, Stidham RW, et al
    CT utilization abruptly increases at age 18 among patients with inflammatory bowel diseases in the hospital.
    PLoS One. 2018;13:e0195022.
    PubMed     Abstract available

  121. CHEN CH, Lin CL, Jeng LB
    Association between chronic pancreatitis and urolithiasis: A population-based cohort study.
    PLoS One. 2018;13:e0194019.
    PubMed     Abstract available

  122. DECLERCQ V, Langille MGI, Van Limbergen J
    Differences in adiposity and diet quality among individuals with inflammatory bowel disease in Eastern Canada.
    PLoS One. 2018;13:e0200580.
    PubMed     Abstract available

  123. PEIRAVAN A, Bertolini F, Rothschild MF, Simpson KW, et al
    Genome-wide association studies of inflammatory bowel disease in German shepherd dogs.
    PLoS One. 2018;13:e0200685.
    PubMed     Abstract available

  124. VAN DER STAR BJ, van Dijk CE, Zock JP, Smit LAM, et al
    Healthcare utilisation prior to the diagnosis of inflammatory bowel diseases and the influence of livestock exposure: A longitudinal case-control study.
    PLoS One. 2018;13:e0195305.
    PubMed     Abstract available

  125. DE MEIJ TGJ, de Groot EFJ, Peeters CFW, de Boer NKH, et al
    Variability of core microbiota in newly diagnosed treatment-naive paediatric inflammatory bowel disease patients.
    PLoS One. 2018;13:e0197649.
    PubMed     Abstract available

  126. ARGENY S, Tamandl D, Scharitzer M, Stift A, et al
    Visceral fat area measured with computed tomography does not predict postoperative course in Crohn s disease patients.
    PLoS One. 2018;13:e0202220.
    PubMed     Abstract available

  127. LE GALL G, Kirchgesner J, Bejaoui M, Landman C, et al
    Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease.
    PLoS One. 2018;13:e0201991.
    PubMed     Abstract available

  128. KAMM F, Strauch U, Degenhardt F, Lopez R, et al
    Correction: Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease.
    PLoS One. 2018;13:e0203709.
    PubMed     Abstract available

  129. EL-MATARY W, Deora V, Grover K
    Barriers to clinical research in children with inflammatory bowel disease: The patients' perspective.
    PLoS One. 2018;13:e0206965.
    PubMed     Abstract available

  130. ADAMS LC, Lubbe F, Bressem K, Wagner M, et al
    Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study.
    PLoS One. 2018;13:e0206450.
    PubMed     Abstract available

  131. PITTET V, Vaucher C, Froehlich F, Maillard MH, et al
    Patient-reported healthcare expectations in inflammatory bowel diseases.
    PLoS One. 2018;13:e0197351.
    PubMed     Abstract available

  132. KUMAGAI J, Taida T, Ogasawara S, Nakagawa T, et al
    Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients.
    PLoS One. 2018;13:e0209352.
    PubMed     Abstract available

  133. HORN MP, Peter AM, Righini Grunder F, Leichtle AB, et al
    PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn's disease.
    PLoS One. 2018;13:e0208974.
    PubMed     Abstract available

  134. ABRON JD, Singh NP, Price RL, Nagarkatti M, et al
    Genistein induces macrophage polarization and systemic cytokine to ameliorate experimental colitis.
    PLoS One. 2018;13:e0199631.
    PubMed     Abstract available

  135. YILMAZ B, Spalinger MR, Biedermann L, Franc Y, et al
    The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients.
    PLoS One. 2018;13:e0199664.
    PubMed     Abstract available

  136. KAUR R, Thakur S, Rastogi P, Kaushal N, et al
    Resolution of Cox mediated inflammation by Se supplementation in mouse experimental model of colitis.
    PLoS One. 2018;13:e0201356.
    PubMed     Abstract available

  137. CAI Q, Li F, Zhou Y
    Experiences of Chinese patients with Crohn's disease in the self-administration of nasogastric feeding: A descriptive qualitative study.
    PLoS One. 2018;13:e0201421.
    PubMed     Abstract available

  138. TAJIRI H, Motoya S, Kinjo F, Maemoto A, et al
    Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.
    PLoS One. 2018;13:e0201956.
    PubMed     Abstract available

  139. SZANTO K, Nyari T, Balint A, Bor R, et al
    Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center.
    PLoS One. 2018;13:e0200824.
    PubMed     Abstract available

  140. LANDMAN C, Grill JP, Mallet JM, Marteau P, et al
    Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota.
    PLoS One. 2018;13:e0202587.
    PubMed     Abstract available

  141. KRUK B, Liebe R, Milkiewicz M, Wunsch E, et al
    PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
    PLoS One. 2018;13:e0202942.
    PubMed     Abstract available

  142. ARTHUR S, Singh S, Sundaram U
    Cyclooxygenase pathway mediates the inhibition of Na-glutamine co-transporter B0AT1 in rabbit villus cells during chronic intestinal inflammation.
    PLoS One. 2018;13:e0203552.
    PubMed     Abstract available

  143. MAHALHAL A, Williams JM, Johnson S, Ellaby N, et al
    Oral iron exacerbates colitis and influences the intestinal microbiome.
    PLoS One. 2018;13:e0202460.
    PubMed     Abstract available

  144. MATSUOKA K, Hamada S, Shimizu M, Nanki K, et al
    Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
    PLoS One. 2018;13:e0204632.
    PubMed     Abstract available

  145. ELLMANN S, Langer V, Britzen-Laurent N, Hildner K, et al
    Application of machine learning algorithms for multiparametric MRI-based evaluation of murine colitis.
    PLoS One. 2018;13:e0206576.
    PubMed     Abstract available

  146. BIELINSKI M, Lesiewska N, Bielinska J, Liebert A, et al
    Affective temperament in inflammatory bowel diseases: Another brick in the wall of differentiation.
    PLoS One. 2018;13:e0205606.
    PubMed     Abstract available

  147. SUDIRMAN S, Hsu YH, He JL, Kong ZL, et al
    Dietary polysaccharide-rich extract from Eucheuma cottonii modulates the inflammatory response and suppresses colonic injury on dextran sulfate sodium-induced colitis in mice.
    PLoS One. 2018;13:e0205252.
    PubMed     Abstract available

  148. MULLER C, Stift A, Argeny S, Bergmann M, et al
    Delta albumin is a better prognostic marker for complications following laparoscopic intestinal resection for Crohn's disease than albumin alone - A retrospective cohort study.
    PLoS One. 2018;13:e0206911.
    PubMed     Abstract available

    January 2017
  149. COSTA PEREIRA C, Duraes C, Coelho R, Gracio D, et al
    Association between Polymorphisms in Antioxidant Genes and Inflammatory Bowel Disease.
    PLoS One. 2017;12:e0169102.
    PubMed     Abstract available

  150. NISHIDA Y, Hosomi S, Yamagami H, Yukawa T, et al
    Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis.
    PLoS One. 2017;12:e0169845.
    PubMed     Abstract available

  151. VRAKAS S, Mountzouris KC, Michalopoulos G, Karamanolis G, et al
    Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease.
    PLoS One. 2017;12:e0170034.
    PubMed     Abstract available

  152. Correction: Inflammatory Bowel Disease: How Effective Is TNF-alpha Suppression?
    PLoS One. 2017;12:e0170865.
    PubMed     Abstract available

  153. SINGH H, Nugent Z, Yu BN, Lix LM, et al
    Hospital discharge abstracts have limited accuracy in identifying occurrence of Clostridium difficile infections among hospitalized individuals with inflammatory bowel disease: A population-based study.
    PLoS One. 2017;12:e0171266.
    PubMed     Abstract available

  154. KUO B, Bhasin M, Jacquart J, Scult MA, et al
    Correction: Genomic and Clinical Effects Associated with a Relaxation Response Mind-Body Intervention in Patients with Irritable Bowel Syndrome and Inflammatory Bowel Disease.
    PLoS One. 2017;12:e0172872.
    PubMed     Abstract available

  155. RANJHA R, Meena NK, Singh A, Ahuja V, et al
    Association of miR-196a-2 and miR-499 variants with ulcerative colitis and their correlation with expression of respective miRNAs.
    PLoS One. 2017;12:e0173447.
    PubMed     Abstract available

  156. LEWIS A, Felice C, Kumagai T, Lai C, et al
    The miR-200 family is increased in dysplastic lesions in ulcerative colitis patients.
    PLoS One. 2017;12:e0173664.
    PubMed     Abstract available

  157. BOR R, Farkas K, Fabian A, Balint A, et al
    Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease.
    PLoS One. 2017;12:e0172916.
    PubMed     Abstract available

  158. TOROK HP, Bellon V, Konrad A, Lacher M, et al
    Functional Toll-Like Receptor (TLR)2 polymorphisms in the susceptibility to inflammatory bowel disease.
    PLoS One. 2017;12:e0175180.
    PubMed     Abstract available

  159. NIRVANAPPA AC, Mohan CD, Rangappa S, Ananda H, et al
    Correction: Novel Synthetic Oxazines Target NF-kappaB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo.
    PLoS One. 2017;12:e0175659.
    PubMed     Abstract available

  160. SULLIVAN E, Piercy J, Waller J, Black CM, et al
    Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.
    PLoS One. 2017;12:e0175826.
    PubMed     Abstract available

  161. PATEL H, Lissoos T, Rubin DT
    Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States.
    PLoS One. 2017;12:e0175099.
    PubMed     Abstract available

  162. MURTHY SK, James PD, Antonova L, Chalifoux M, et al
    High end of life health care costs and hospitalization burden in inflammatory bowel disease patients: A population-based study.
    PLoS One. 2017;12:e0177211.
    PubMed     Abstract available

  163. PUGAZHENDHI S, Baskaran K, Santhanam S, Ramakrishna BS, et al
    Association of ATG16L1 gene haplotype with inflammatory bowel disease in Indians.
    PLoS One. 2017;12:e0178291.
    PubMed     Abstract available

  164. TIMMER A, Peplies J, Westphal M, Kaltz B, et al
    Transition from pediatric to adult medical care - A survey in young persons with inflammatory bowel disease.
    PLoS One. 2017;12:e0177757.
    PubMed     Abstract available

  165. SCHIEFFER KM, Bruffy SM, Rauscher R, Koltun WA, et al
    Reduced total serum bilirubin levels are associated with ulcerative colitis.
    PLoS One. 2017;12:e0179267.
    PubMed     Abstract available

  166. DE PALMA GD, Colavita I, Zambrano G, Giglio MC, et al
    Detection of colonic dysplasia in patients with ulcerative colitis using a targeted fluorescent peptide and confocal laser endomicroscopy: A pilot study.
    PLoS One. 2017;12:e0180509.
    PubMed     Abstract available

  167. CUI Y, Zhu C, Ming Z, Cao J, et al
    Molecular mechanisms by which casein glycomacropeptide maintains internal homeostasis in mice with experimental ulcerative colitis.
    PLoS One. 2017;12:e0181075.
    PubMed     Abstract available

  168. VILLORIA A, Garcia V, Dosal A, Moreno L, et al
    Fatigue in out-patients with inflammatory bowel disease: Prevalence and predictive factors.
    PLoS One. 2017;12:e0181435.
    PubMed     Abstract available

  169. VITALE S, Strisciuglio C, Pisapia L, Miele E, et al
    Cytokine production profile in intestinal mucosa of paediatric inflammatory bowel disease.
    PLoS One. 2017;12:e0182313.
    PubMed     Abstract available

  170. PITTET V, Vaucher C, Froehlich F, Burnand B, et al
    Patient self-reported concerns in inflammatory bowel diseases: A gender-specific subjective quality-of-life indicator.
    PLoS One. 2017;12:e0171864.
    PubMed     Abstract available

  171. HAMPSHIRE T, Menys A, Jaffer A, Bhatnagar G, et al
    A Probabilistic Method for Estimation of Bowel Wall Thickness in MR Colonography.
    PLoS One. 2017;12:e0168317.
    PubMed     Abstract available

  172. WILLIAMS AD, Korolkova OY, Sakwe AM, Geiger TM, et al
    Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease.
    PLoS One. 2017;12:e0179710.
    PubMed     Abstract available

  173. IJAZ UZ, Quince C, Hanske L, Loman N, et al
    The distinct features of microbial 'dysbiosis' of Crohn's disease do not occur to the same extent in their unaffected, genetically-linked kindred.
    PLoS One. 2017;12:e0172605.
    PubMed     Abstract available

  174. STIDHAM RW, Wu J, Shi J, Lubman DM, et al
    Serum Glycoproteome Profiles for Distinguishing Intestinal Fibrosis from Inflammation in Crohn's Disease.
    PLoS One. 2017;12:e0170506.
    PubMed     Abstract available

  175. MICIC D, Gaetano JN, Rubin JN, Cohen RD, et al
    Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease.
    PLoS One. 2017;12:e0182900.
    PubMed     Abstract available

  176. PEREIRA SR, Pereira R, Figueiredo I, Freitas V, et al
    Comparison of anti-inflammatory activities of an anthocyanin-rich fraction from Portuguese blueberries (Vaccinium corymbosum L.) and 5-aminosalicylic acid in a TNBS-induced colitis rat model.
    PLoS One. 2017;12:e0174116.
    PubMed     Abstract available

  177. DIAS CC, Pereira Rodrigues P, Fernandes S, Portela F, et al
    The risk of disabling, surgery and reoperation in Crohn's disease - A decision tree-based approach to prognosis.
    PLoS One. 2017;12:e0172165.
    PubMed     Abstract available

  178. SABE VT, Basson AR, Jordaan E, Mazinu M, et al
    The association between environmental exposures during childhood and the subsequent development of Crohn's disease: A score analysis approach.
    PLoS One. 2017;12:e0171742.
    PubMed     Abstract available

  179. MONASTA L, Pierobon C, Princivalle A, Martelossi S, et al
    Inflammatory bowel disease and patterns of volatile organic compounds in the exhaled breath of children: A case-control study using Ion Molecule Reaction-Mass Spectrometry.
    PLoS One. 2017;12:e0184118.
    PubMed     Abstract available

  180. SARID O, Slonim-Nevo V, Pereg A, Friger M, et al
    Coping strategies, satisfaction with life, and quality of life in Crohn's disease: A gender perspective using structural equation modeling analysis.
    PLoS One. 2017;12:e0172779.
    PubMed     Abstract available

  181. PALMIERI O, Bossa F, Valvano MR, Corritore G, et al
    Crohn's Disease Localization Displays Different Predisposing Genetic Variants.
    PLoS One. 2017;12:e0168821.
    PubMed     Abstract available

  182. OKAHARA K, Nagata N, Shimada T, Joya A, et al
    Colonic cytomegalovirus detection by mucosal PCR and antiviral therapy in ulcerative colitis.
    PLoS One. 2017;12:e0183951.
    PubMed     Abstract available

  183. RANJHA R, Meena NK, Singh A, Ahuja V, et al
    Correction: Association of miR-196a-2 and miR-499 variants with ulcerative colitis and their correlation with expression of respective miRNAs.
    PLoS One. 2017;12:e0184701.
    PubMed     Abstract available

  184. IRWIN J, Ferguson E, Simms LA, Hanigan K, et al
    A rolling phenotype in Crohn's disease.
    PLoS One. 2017;12:e0174954.
    PubMed     Abstract available

  185. MENGHINI P, Di Martino L, Lopetuso LR, Corridoni D, et al
    A novel model of colitis-associated cancer in SAMP1/YitFc mice with Crohn's disease-like ileitis.
    PLoS One. 2017;12:e0174121.
    PubMed     Abstract available

  186. SHIMADA T, Nagata N, Okahara K, Joya A, et al
    PCR detection of human herpesviruses in colonic mucosa of individuals with inflammatory bowel disease: Comparison with individuals with immunocompetency and HIV infection.
    PLoS One. 2017;12:e0184699.
    PubMed     Abstract available

  187. OH K, Oh EH, Baek S, Song EM, et al
    Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease.
    PLoS One. 2017;12:e0179266.
    PubMed     Abstract available

  188. AL-JARALLAH A, Oriowo M
    The effect of sphingosine-1-phosphate on colonic smooth muscle contractility: Modulation by TNBS-induced colitis.
    PLoS One. 2017;12:e0170792.
    PubMed     Abstract available

  189. TOYONAGA T, Kobayashi T, Nakano M, Saito E, et al
    Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome.
    PLoS One. 2017;12:e0185131.
    PubMed     Abstract available

  190. KIM Y, Wu AG, Jaja-Chimedza A, Graf BL, et al
    Isothiocyanate-enriched moringa seed extract alleviates ulcerative colitis symptoms in mice.
    PLoS One. 2017;12:e0184709.
    PubMed     Abstract available

  191. BAMBA S, Sasaki M, Takaoka A, Takahashi K, et al
    Sarcopenia is a predictive factor for intestinal resection in admitted patients with Crohn's disease.
    PLoS One. 2017;12:e0180036.
    PubMed     Abstract available

  192. PENG YC, Lin CL, Sung FC
    The association between cholecystectomy and colorectal neoplasm in inflammatory bowel diseases: A population-based cohort study.
    PLoS One. 2017;12:e0177745.
    PubMed     Abstract available

  193. OH EH, Oh K, Han M, Seo H, et al
    Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors.
    PLoS One. 2017;12:e0177479.
    PubMed     Abstract available

  194. SOMASUNDARAM R, Fernandes S, Deuring JJ, de Haar C, et al
    Analysis of SHIP1 expression and activity in Crohn's disease patients.
    PLoS One. 2017;12:e0182308.
    PubMed     Abstract available

  195. HENNENBERG EM, Eyking A, Reis H, Cario E, et al
    MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis.
    PLoS One. 2017;12:e0180834.
    PubMed     Abstract available

  196. ANDERSSON E, Bergemalm D, Kruse R, Neumann G, et al
    Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles.
    PLoS One. 2017;12:e0186142.
    PubMed     Abstract available

  197. PILLAI N, Dusheiko M, Burnand B, Pittet V, et al
    A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease.
    PLoS One. 2017;12:e0185500.
    PubMed     Abstract available

  198. TAKAYASU L, Suda W, Watanabe E, Fukuda S, et al
    A 3-dimensional mathematical model of microbial proliferation that generates the characteristic cumulative relative abundance distributions in gut microbiomes.
    PLoS One. 2017;12:e0180863.
    PubMed     Abstract available

  199. HAN YM, Koh J, Kim JW, Lee C, et al
    NF-kappa B activation correlates with disease phenotype in Crohn's disease.
    PLoS One. 2017;12:e0182071.
    PubMed     Abstract available

  200. SJOBERG F, Barkman C, Nookaew I, Ostman S, et al
    Low-complexity microbiota in the duodenum of children with newly diagnosed ulcerative colitis.
    PLoS One. 2017;12:e0186178.
    PubMed     Abstract available

  201. CHEN L, Zhou Z, Yang Y, Chen N, et al
    Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice.
    PLoS One. 2017;12:e0186138.
    PubMed     Abstract available

  202. MORTENSEN JH, Manon-Jensen T, Jensen MD, Hagglund P, et al
    Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
    PLoS One. 2017;12:e0185855.
    PubMed     Abstract available

  203. PERRY T, Laffin M, Fedorak RN, Thiesen A, et al
    Ileocolic resection is associated with increased susceptibility to injury in a murine model of colitis.
    PLoS One. 2017;12:e0184660.
    PubMed     Abstract available

  204. SCALDAFERRI F, D'Ambrosio D, Holleran G, Poscia A, et al
    Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.
    PLoS One. 2017;12:e0186575.
    PubMed     Abstract available

  205. FAGAGNINI S, Heinrich H, Rossel JB, Biedermann L, et al
    Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases.
    PLoS One. 2017;12:e0185193.
    PubMed     Abstract available

  206. FUKUDA T, Naganuma M, Sugimoto S, Nanki K, et al
    The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry.
    PLoS One. 2017;12:e0187737.
    PubMed     Abstract available

  207. SEKIZUKA T, Ogasawara Y, Ohkusa T, Kuroda M, et al
    Characterization of Fusobacterium varium Fv113-g1 isolated from a patient with ulcerative colitis based on complete genome sequence and transcriptome analysis.
    PLoS One. 2017;12:e0189319.
    PubMed     Abstract available

  208. LIN WC, Chang CW, Chen MJ, Chu CH, et al
    Challenges in the diagnosis of ulcerative colitis with concomitant bacterial infections and chronic infectious colitis.
    PLoS One. 2017;12:e0189377.
    PubMed     Abstract available

  209. HOLTMAN GA, Lisman-van Leeuwen Y, Kollen BJ, Norbruis OF, et al
    Diagnostic test strategies in children at increased risk of inflammatory bowel disease in primary care.
    PLoS One. 2017;12:e0189111.
    PubMed     Abstract available

  210. WILLIAMS AD, Korolkova OY, Sakwe AM, Geiger TM, et al
    Correction: Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease.
    PLoS One. 2017;12:e0189551.
    PubMed     Abstract available

  211. SARGIN ZG, Erin N, Tazegul G, Elpek GO, et al
    Profound loss of neprilysin accompanied by decreased levels of neuropeptides and increased CRP in ulcerative colitis.
    PLoS One. 2017;12:e0189526.
    PubMed     Abstract available

  212. LEE JH, Kim TJ, Kim ER, Hong SN, et al
    Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn's disease.
    PLoS One. 2017;12:e0188925.
    PubMed     Abstract available

    January 2016
  213. NIRVANAPPA AC, Mohan CD, Rangappa S, Ananda H, et al
    Novel Synthetic Oxazines Target NF-kappaB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo.
    PLoS One. 2016;11:e0163209.
    PubMed     Abstract available

  214. BEN-SHACHAR S, Yanai H, Sherman Horev H, Elad H, et al
    Correction: MicroRNAs Expression in the Ileal Pouch of Patients with Ulcerative Colitis Is Robustly Up-Regulated and Correlates with Disease Phenotypes.
    PLoS One. 2016;11:e0165220.
    PubMed     Abstract available

  215. VICKERS AD, Ainsworth C, Mody R, Bergman A, et al
    Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    PLoS One. 2016;11:e0165435.
    PubMed     Abstract available

  216. HSU TY, Shih HM, Wang YC, Lin LC, et al
    Effect of Alcoholic Intoxication on the Risk of Inflammatory Bowel Disease: A Nationwide Retrospective Cohort Study.
    PLoS One. 2016;11:e0165411.
    PubMed     Abstract available

  217. SUNDARRAJAN S, Arumugam M
    Comorbidities of Psoriasis - Exploring the Links by Network Approach.
    PLoS One. 2016;11:e0149175.
    PubMed     Abstract available

  218. LO WC, Arsenescu V, Arsenescu RI, Friedman A, et al
    Inflammatory Bowel Disease: How Effective Is TNF-alpha Suppression?
    PLoS One. 2016;11:e0165782.
    PubMed     Abstract available

  219. MANGUSO F, Bennato R, Lombardi G, Riccio E, et al
    Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0166455.
    PubMed     Abstract available

  220. CHIAPPONI C, Witt M, Dlugosch GE, Gulberg V, et al
    The Perception of Physician Empathy by Patients with Inflammatory Bowel Disease.
    PLoS One. 2016;11:e0167113.
    PubMed     Abstract available

  221. DONG J, Teng G, Wei T, Gao W, et al
    Methodological Quality Assessment of Meta-Analyses and Systematic Reviews of Probiotics in Inflammatory Bowel Disease and Pouchitis.
    PLoS One. 2016;11:e0168785.
    PubMed     Abstract available

  222. ZHANG F, Xu C, Ning L, Hu F, et al
    Exploration of Serum Proteomic Profiling and Diagnostic Model That Differentiate Crohn's Disease and Intestinal Tuberculosis.
    PLoS One. 2016;11:e0167109.
    PubMed     Abstract available

  223. ZEITZ J, Ak M, Muller-Mottet S, Scharl S, et al
    Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account.
    PLoS One. 2016;11:e0156666.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.